A newly approved therapy, bepirovirsen, can deliver a functional cure in roughly 1 in 5 patients with chronic hepatitis B — but most will never qualify for it, because quantitative HBsAg testing that identifies candidates remains absent from routine screening and primary care, specialists warned this month in a roundtable reported by The American Journal of Managed Care.
The gap is stark. Bepirovirsen (Hibsago, GSK) was approved in October 2026 after phase 3 trials, and long-term data presented at The Liver Meeting 2026 in Denver showed that 19% of treated patients achieved functional cure at week 72, with 91% of those maintaining it at week 96, Gastroenterology & Endoscopy News reported.
Yet the test that tells doctors which patients sit in the drug’s sweet spot — a low quantitative hepatitis B surface antigen (HBsAg) level — rarely arrives with referred patients. “Few patients arrive at specialty clinics with a quantitative HBsAg result,” the specialists told AJMC.
Why it matters now: chronic hepatitis B affects millions worldwide, and standard nucleos(t)ide analogue (NA) therapy suppresses the virus but almost never clears surface antigen — spontaneous clearance runs at less than 1% per year on existing therapy, according to trial investigator Man-Fung Yuen of the University of Hong Kong, as reported by Gastroenterology & Endoscopy News.
A finite, roughly six-month injection course offering durable cure changes the calculus — if patients and their doctors can find out who qualifies.
Functional Cure Ends Daily Pills but Is Not Total Eradication
- A “functional cure” means the virus is controlled and the virus’s surface protein (HBsAg) disappears from the blood — with or without protective antibodies — after finishing treatment. It is not total eradication, but it ends daily pills and, for many patients, the fear of passing the virus on.
- Bepirovirsen works best in patients whose HBsAg level is already low. Standard hepatitis B screening only says “positive” or “negative”; it does not measure how much surface antigen is present.
- Roughly a 1-in-5 chance of cure means 4 in 5 patients on the drug will not be cured — an honest conversation every candidate should have before starting.
Two Numbers That Define the Promise
The B-Well 1 and B-Well 2 trials were global, phase 3, double-blind studies — meaning neither patients nor investigators knew who received drug versus placebo — enrolling adults without cirrhosis whose virus was suppressed on NA therapy. Participants received 300 mg of bepirovirsen or placebo weekly for 24 weeks. In the pooled analysis presented at The Liver Meeting 2026 (poster 0266), 24% of bepirovirsen-treated patients entered the durability stage.
| Outcome (B-Well pooled analysis) | All bepirovirsen patients | HBsAg ≤ 1,000 IU/mL |
|---|---|---|
| Functional cure at week 72 | 19% | 26% |
| Durable cure maintained at week 96 | 91% of those cured | 91% of those cured |
| Entered durability stage | 24% (n=291) | — |
The contrast with existing care is the story’s engine. On nucleos(t)ide analogues, functional cure occurs in fewer than 1% of patients per year, Yuen noted. Bepirovirsen’s mechanism of action differs fundamentally: it is an antisense oligonucleotide, a laboratory-designed snippet of genetic material that binds to the virus’s RNA messages and stops production of viral proteins, including surface antigen.
Functional cure was defined in the trials as 24 weeks or more of sustained HBV DNA below the limit of quantification plus HBsAg loss after finite therapy, with or without surface antibody.
The Test That Isn’t Being Ordered
Roundtable panelists — including Tatyana Kushner of Weill Cornell Medicine (moderator), Mark S. Sulkowski of Johns Hopkins, and Su Wang of RWJBarnabas Health — discussed asking commercial laboratories to build reflex quantitative HBsAg testing, which would automatically run the measurement after any positive surface antigen result. One participant cautioned this can be difficult to set up, AJMC reported.
The practical barriers are real. One panelist said ordering the test is simple once it lives in the electronic health record, but his health system needed nearly two years to add it. Another said dependence on commercial laboratories had limited how often he tested.
Sulkowski has measured quantitative HBsAg at initial evaluation and annually for four years and said the result shows how close treated patients may be to functional cure. Ype P. de Jong of Weill Cornell now orders it at return visits for all patients with chronic hepatitis B.
Treating Beyond the Guidelines
Because phase 3 participants had to be on NA therapy, faculty said they are starting NAs in “gray-zone” patients with low HBsAg who previously declined treatment — positioning them for bepirovirsen. AJMC said that several panelists go past the thresholds set by guidelines, viewing alanine aminotransferase (ALT) cutoffs as obsolete and basing decisions instead on fibrosis, age, viral load, and family history of liver cancer.
What Six Months of Weekly Injections Demands
Patients used to a daily pill and twice-yearly visits will face about six months of weekly injections and labs monitoring ALT flares — sudden enzyme spikes signaling liver inflammation — and low platelet counts.
Mark Makhinson, PharmD, of Mount Sinai Health System, said the large New York–New Jersey systems at the roundtable have strong specialty pharmacies handling prior authorization, financial assistance, and monthly adherence checks, but added: "I think it's really positive, but…that is likely not the norm everywhere," in remarks to AJMC.
According to Sulkowski, the group is trying to restore pharmacy partnerships from the hepatitis C era that have mostly fallen apart, and to funnel prescribing to a handful of bepirovirsen champions instead of spreading it across all 15 clinicians who treat hepatitis B — relying on advanced practice providers to manage follow-up and using 340B Drug Pricing Program revenue to pay for those hires.
Wang suggested standing weekly lab orders, telehealth support, and ECHO-style learning networks — telementoring models that extend specialist knowledge to community clinicians — to stretch capacity beyond hepatology departments.
Panelists Stress Candid Talks About Low Cure Odds
A roughly 1-in-5 chance of functional cure is progress, participants said, but it demands candid conversations about the odds. Before putting patients forward for a treatment with only about a 20% success rate, one panelist wants to see real-world results in their own patient population first, AJMC reported.
Wang pointed to a benefit trials do not capture: relief from stigma.
“Patients, they feel infectious; [then] they worry about giving it to their family members, and there’s a shame about that,” Wang told AJMC. “Being able to say, ‘I lost my surface antigen’ is very liberating for them.”
Contraindications & When to Consult a Doctor
The trials that support bepirovirsen’s approval enrolled adults without cirrhosis whose virus was suppressed on NA therapy; patients with cirrhosis were not studied in this population, so candidacy should be assessed with a hepatitis B specialist. During treatment, weekly monitoring is required for ALT flares and low platelet counts — both of which can signal liver injury or bleeding risk.
Anyone with chronic hepatitis B who develops worsening fatigue, abdominal swelling, jaundice, easy bruising, or dark urine should contact their clinician promptly. Screening decisions belong with a doctor; current U.S. screening recommendations are maintained by organizations such as the Hepatitis B Foundation, and patients should not start or stop antiviral therapy on their own.
Where This Leaves Patients
The approval and the durability data mark real progress; the screening and infrastructure gaps determine who actually reaches it. The phase 3 results were published in the New England Journal of Medicine this year, and the roundtable specialists’ prescription is unambiguous: without reflex quantitative HBsAg testing reaching primary care, the patients most likely to benefit from a finite cure will be the ones least likely to find it.
References
- McCormick B. “Bepirovirsen approval offers new option for chronic HBV treatment.” The American Journal of Managed Care. October 21, 2026.
- Hou J, Lim SG, Buti M, et al. “Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection.” N Engl J Med. 2026;394(24):2395-2406. doi:10.1056/NEJMoa2515131.
- “Bepirovirsen Demonstrates Durable Functional Cure in HBV.” Gastroenterology & Endoscopy News. The Liver Meeting 2026, poster 0266.
- Hepatitis B Foundation. U.S. screening recommendations.
Readers should consult a qualified healthcare provider regarding diagnosis and treatment of hepatitis B.